Zusammenfassung
Der Morbus Behçet führt bei natürlichem Verlauf, das heißt unbeeinflußt von therapeutischen Maßnahmen, in einem hohen Prozentsatz zur Erblindung. Die Krankheitsaktivität ist jedoch von Patient zu Patient unterschiedlich und bestimmt die Zuordnung zu einer schweren Verlaufsform („Majorform“) oder einer leichten Verlaufs-form („Minorform“). Dementsprechend differenziert muß der Einsatz der immunsuppressiven Therapeutika erfolgen. In der vorliegenden Zusammenfassung werden die Vor- und Nachteile der einzelnen Medikamente unter Berücksichtigung ihrer Nebenwirkungen diskutiert. Es wird an Hand von zwei Fallbeispielen, die die zwei Verlaufsformen des M. Behçet repräsentieren, unser Therapieschema vorgestellt.
Summary
Taking it’s natural course M. Behçet leads to blindness in a high percentage of cases. The activity of the illness varies and can be described by “major”- or “minorforms”. According to the severity of the disease the immunosuppressiv therapy will be administered. In this review the advantages and disatvantages of these immunosuppressiv drugs considering also their side effects shall be discussed. We report on two male patients, who suffer from different forms of the illness, and furthermore we present our own therapeutic regiment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Benezra D, Cohen E (1986) Treatment and visual prognosis in Behçet’s disease. Br J Ophthalmol 70: 589–592
Chavis P, Antonios S, Tabbara K (1992) Cyclosporine effects on optic nerve and retinal vaskulitis in Behçet’s disease. Doc Ophthalmol 80: 133–142
Cochereau-Massin I, Wechsler B, Le Hoang P, Huong Du L, Cirard B, Rousselie F, Godeau P (1992) Pronostic oculair de la maladie de Behçet. J Fr Ophthalmol 15/5: 343–347
De Vries J, Baarsma G, Zaal M, Boen-Tan N, Rothova A, Buitenhuis H, Schweitzer C, De Keizer R, Kijlstra A (1990) Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 74: 344–349
Mamo J (1970) The rate of visual loss in Behçet’s disease. Arch Ophthalmol 84: 451–452
Masuda K, Nakajima A, Urayama A, Kogure M, Nakae K, Inaba G (1989) Double-masked trial of cyclosporin versus colchicin and long-term open study of cyclosporin in Behçet’s disease. Lancet 1989: 1093–1096
Müftüoglu A, Pazarli H, Yurdakul S, Yazici H, Ülkü B, Tüzün Y, Serdaroglu S, Altug E, Bahçecioglu H, Güngen G (1987) Short term cyclosporin A treatment of Behçet’s disease. Br J Ophthalmol 71: 387–390
Nussenblatt R, Palestine A, Chan CC (1983) Cyclorporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 96/3: 275–281
O’Duffy D, Robertson D, Goldstein N (1984) Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet’s disease. Am J Med 76: 75–83
O’Duffy D (1989) Behçet’s disease. In: Lelley W, Harris E, Ruddy S et al (eds) Textbook of rheumatology, 3rd edn., pp 1209–1214. W. B. Saunders, Philadelphia London Toronto
Ohno S, Ohguchi M, Hirroshe S, Matsuda H, Wakisaka A, Aizawa M (1982) Close Association of HLA-B 51 with Behçet’s Disease. Arch Ophthalmol 100: 1455–1458
Özyazgan Y, Yurdakul S, Yazici H, Tüzün B, Iscimen A, Tüzün Y, Aktunç T, Pazarli H, Hamuryudan V, Müftüoglu A (1992) Low dose cyclosporin A versus pulsed cyclophosphamid in Behçet’s disease: a single masked trial. Br J Ophthalmol 76: 241–243
Powell R, Dunstan S (1991) Immunpathology of Behçet’s disease. Postgrad Med J 67: 503–505
Soylu M, Ersöz R, Erken E (1992) The association between HLA B 5 and ocular involvment in Behçet’s disease in southern Turkey. Acta Ophthalmologica 70: 786–789
Tabbara K (1983) Chlorambucil in Behçet’s disease. A reappraisal. Ophthalmology 90: 906–908
Tessler H, Jennings T (1990) High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet’s disease. Br J Ophthalmol 74: 353–357
The International Study Group for Behçet’s Disease (1992) Evaluation of diagnostic (‘Classification’) criteria in Behçet’s disease - towards internationally agreed criteria. Br J Rheumatol 31: 299–308
Towler H, Lightman S, Forrester J (1992) Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a longterm follow-up suty. J Autoimmunity 5 [Suppl A]: 259–264
Yazici H, Pazarli H, Barnes C, Tüzün Y, Özyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt G, Yazici B, Somani S, Müftüoglu A (1990) A controlled trial of azathioprin in Behçet’s syndrome. New Engl J Med 322/5: 281–285
Zouboulis C, Büttner P, Djawari D, Kirch W, Keitel W, Garbe C, von Keyserlingk-Eberius H, Orfanos C (1993) HLA-Muster bei Morbus Amantiades-Behçet in Deutschland. Der Hautarzt 44: 81–85
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ries, E., Velikay, M., Schauersberger, J. et al. Morbus Behçet — eine Übersicht mit pharmakotherapeutischem Schwerpunkt. Spektrum Augeheilkd 9, 39–42 (1995). https://doi.org/10.1007/BF03163733
Issue Date:
DOI: https://doi.org/10.1007/BF03163733